Abstract
Capsule endoscopy and balloon endoscopy, advanced modalities that now allow for full investigation of the entire small intestine, have revealed that non-steroidal anti-inflammatory drugs (NSAIDs) can cause a variety of abnormalities in the small intestine. Traditional NSAIDs can induce small intestinal injuries in over 50% of patients. Several studies have shown that the preventive effect of proton pump inhibitors does not extend to the small intestine, suggesting that concomitant therapy may be required to prevent small intestinal side effects associated with traditional NSAIDs use. Recently, several randomized controlled trials used capsule endoscopy to evaluate the preventive effect of certain drugs on NSAID-induced small intestinal injuries. These studies show that misoprostol and rebamipide have a preventive effect for NSAID-induced small intestinal mucosal injuries. However, these studies included only a small series of healthy volunteers and tested short-term NSAID treatment. Therefore, further extensive studies are clearly required to ascertain the beneficial effect of these drugs.
Journal Section:
Original Paper
References
1.
Fries JF, Williams CA, Bloch DA, Michel BA: Non-steroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213–222.
[PubMed]
2.
Smalley WE, Ray WA, Daugherty JR, Griffin MR: Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539–545.
[PubMed]
3.
Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI: Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992;327:749–754.
[PubMed]
4.
Bjarnason I, Hayllar J, MacPherson AJ, Russell AS: Side effects of non-steroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832–1847.
[PubMed]
5.
Morris AJ, MacKenzie JF: Small bowel enteroscopy in undiagnosed gastrointestinal blood loss. Gut 1992;33:887–889.
[PubMed]
6.
Iddan G, Meron G, Glukhorsky A, Swain P: Wireless capsule endoscopy. Nature 2000;405:417.
[PubMed]
7.
Yamamoto H, Sekine Y, Sato Y, Higashizawa T, Miyata T, Iino S, Ido K, Sugano K: Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointest Endosc 2001;53:216–220.
[PubMed]
8.
Morris AJ, Madhok R, Sturrock RD, Capell HA, MacKenzie JF: Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet 1991;337:1093–1094.
9.
Fujimori S, Seo T, Gudis K, Tanaka S, Mitsui K, Kobayashi T, Ehara A, Yonezawa M, Tatsuguchi A, Sakamoto C: Diagnosis and treatment of obscure gastrointestinal bleeding using combined capsule endoscopy and double-balloon endoscopy: 1-year follow-up study. Endoscopy 2007;39:1053–1058.
[PubMed]
10.
Matsumoto T, Kudo T, Esaki M, Yano T, Yamamoto H, Sakamoto C, Goto H, Nakase H, Tanaka S, Matsui T, Sugano K, Iida M: Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol 2008;43:490–496.
[PubMed]
11.
Kent TH, Cardelli RM, Stamler FW: Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 1969;54:237–249.
[PubMed]
12.
Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I: A quantitative analysis of NSAID-induced small bowel pathology by capsule endoscopy. Gastroenterology 2005;128:1172–1178.
[PubMed]
13.
Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133–141.
[PubMed]
14.
Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, Bjarnason I: COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double-blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000;47:527–532.
[PubMed]
15.
Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I: Mitochondrial damage: a possible mechanism of the ‘topical’ phase of NSAID-induced injury to the rat intestine. Gut 1997;41:344–353.
[PubMed]
16.
Somasundaram S, Sigthorsson G, Simpson RJ, Watts J, Jacob M, Tavares IA, Rafi S, Roseth A, Foster R, Price AB, Wrigglesworth JM, Bjarnason I: Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID enteropathy in the rat. Aliment Pharmacol Ther 2000;14:639–650.
[PubMed]
17.
Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Aisenberg J, Bhadra P, Berger MF: Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007;15:1211–1222.
18.
Hawkey CJ: Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000;119:521–535.
[PubMed]
19.
Miller TA: Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983;245:G601–G623.
[PubMed]
20.
Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241–249.
[PubMed]
21.
Gudis K, Samamoto C: The role of cycloxygenase in gastric mucosal protection. Dig Dis Sci 2005;50:S16–S23.
[PubMed]
22.
Bjarnason I, Williams P, So A, Zanelli GD, Levi AJ, Gumpel JM, Peters TJ, Ansell B: Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 1984;2:1171–1174.
[PubMed]
23.
Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ: Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989;34:407–411.
[PubMed]
24.
Fujimori S, Seo T, Gudis K, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C: Prevention of NSAID-induced small intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointestinal Endosc 2009;69:1339–1346.
[PubMed]
25.
Graham DY, Opekun AR, Willingham FF, Qureshi WA: Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005:3:55–59.
[PubMed]
26.
Watanabe T, Sugimori S, Kameda N, Machida H, Okazaki H, Tanigawa T, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Higuchi K, Arakawa T: Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008;6:1279–1282.
[PubMed]
27.
Park SH, Cho CS, Lee OY, Jun JB, Lin SR, Zhou LY, Yuan YZ, Li ZS, Hou XH, Zhao HC, Kachintorn U, Kositchaiwat C, Lertkupinit C: Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial – Storm Study. J Clin Biochem Nutr 2007;40:148–155.
[PubMed]
28.
Terano A, Arakawa T, Sugiyama T, Suzuki H, Joh T, Yoshikawa T, Higuchi K, Haruma K, Murakami K, Kobayashi K, Rebamipide Clinical Study Group: Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 2007;42:690–693.
[PubMed]
29.
Kim HK, Kim JI, Kim JK, Han JY, Park SH, Choi KY, Chung IS: Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci 2007;52:1776–1782.
[PubMed]
30.
Sakurai K, Sasabe H, Koga T, Konishi T: Mechanism of hydroxyl radical scavenging by rebamipide: identification of monohydroxylated rebamipide as a major reaction product. Free Radic Res 2004;38:487–494.
[PubMed]
31.
Chitapanarux T, Praisontarangkul OA, Lertprasertsuke N: An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Dig Dis Sci 2008;53:2896–2903.
[PubMed]
32.
Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K: Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol 2001;16:1112–1119.
[PubMed]
33.
Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, Hirooka Y, Goto H: Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol 2008;43:270–276.
[PubMed]
34.
Fujimori S, Seo T, Takahashi Y, Gudis K, Yamada Y, Tatsuguchi A, Ehara A, Kobayashi T, Mitsui K, Tanaka S, Sakamoto C: Prevention of NSAID-induced small intestinal injury by rebamipide: a prospective, double-blind, randomized controlled trial using capsule endoscopy. Gastroenterology 2009;136(suppl 1):A880.
35.
Fujimori S, Gudis K, Takahashi Y, Yamada Y, Seo T, Tatsuguchi A, Ehara A, Kobayashi T, Mitsui K, Tanaka S, Sakamoto C: Distribution of small intestinal mucosal injuries with short-term administration of non-steroidal anti-inflammatory drugs. Gastrointest Endosc 2009;69:AB100.
36.
Niwa Y, Nakamura M, Miyahara R, Ohmiya N, Watanabe O, Ando T, Kawashima H, Itoh A, Hirooka Y, Goto H: Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study. Digestion 2009;80:260–266.
[PubMed]
37.
Yanaka A, Zhang S, Sato D, Tauchi M, Suzuki H, Shibahara T, Matsui H, Nakahara A, Hyodo I: Geranylgeranylacetone protects the human gastric mucosa from diclofenac-induced injury via induction of heat-shock protein-70. Digestion 2007;75:148–155.
[PubMed]
38.
Sakamoto C, Ogoshi K, Saigenji K, Narisawa R, Nagura H, Mine T, Tada M, Umegaki E, Maekawa T, Maekawa R, Maeda K: Comparison of the effectiveness of geranylgeranylacetone with cimetidine in gastritis patients with dyspeptic symptoms and gastric lesions: a randomized, double-blind trial in Japan. Digestion 2007;75:215–224.
[PubMed]
39.
Marchbank T, Limdi JK, Mahmood A, Elia G, Playford RJ: Clinical trial: protective effect of a commercial fish protein hydrolysate against indomethacin (NSAID)-induced small intestinal injury. Aliment Pharmacol Ther 2008;28:799–804.
[PubMed]
40.
Fitzgerald AJ, Rai PS, Marchbank T, Taylor GW, Ghosh S, Ritz BW, Playford RJ: Reparative properties of a commercial fish protein hydrolysate preparation. Gut 2005;54:775–781.
[PubMed]
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.
